UX111 for treating mucopolysaccharidosis type IIIA [ID6540]

  • Awaiting development
  • GID-TA11701
  • Expected publication date: TBC

Suggested remit: To appraise the clinical and cost effectiveness of UX111 within its marketing authorisation for treating mucopolysaccharidosis type IIIA